Vivimusta is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 29, 2042. Details of Vivimusta's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11844784 | Stable pharmaceutical compositions of bendamustine |
Jul, 2042
(17 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vivimusta's patents.
Latest Legal Activities on Vivimusta's Patents
Given below is the list of recent legal activities going on the following patents of Vivimusta.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 20 Dec, 2023 | US11844784 |
| Recordation of Patent Grant Mailed Critical | 19 Dec, 2023 | US11844784 |
| Recordation of Patent eGrant | 19 Dec, 2023 | US11844784 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Dec, 2023 | US11844784 |
| Patent eGrant Notification | 19 Dec, 2023 | US11844784 |
| Mail Patent eGrant Notification | 19 Dec, 2023 | US11844784 |
| Email Notification Critical | 30 Nov, 2023 | US11844784 |
| Issue Notification Mailed Critical | 29 Nov, 2023 | US11844784 |
| Application Is Considered Ready for Issue Critical | 13 Nov, 2023 | US11844784 |
| Dispatch to FDC | 13 Nov, 2023 | US11844784 |
US patents provide insights into the exclusivity only within the United States, but Vivimusta is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vivimusta's family patents as well as insights into ongoing legal events on those patents.
Vivimusta's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vivimusta's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 29, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vivimusta Generic API suppliers:
Bendamustine Hydrochloride is the generic name for the brand Vivimusta. 11 different companies have already filed for the generic of Vivimusta, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vivimusta's generic
Alternative Brands for Vivimusta
There are several other brand drugs using the same active ingredient (Bendamustine Hydrochloride) as Vivimusta. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bendamustine Hydrochloride, Vivimusta's active ingredient. Check the complete list of approved generic manufacturers for Vivimusta
About Vivimusta
Vivimusta is a drug owned by Azurity Pharmaceuticals Inc. Vivimusta uses Bendamustine Hydrochloride as an active ingredient. Vivimusta was launched by Azurity in 2022.
Approval Date:
Vivimusta was approved by FDA for market use on 07 December, 2022.
Active Ingredient:
Vivimusta uses Bendamustine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Bendamustine Hydrochloride ingredient
Dosage:
Vivimusta is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/4ML (25MG/ML) | SOLUTION | Prescription | INTRAVENOUS |